Burden of respiratory syncytial virus hospitalisation among infants born at 32–35 weeks' gestational age in the Northern Hemisphere: pooled analysis of seven studies. (17th August 2020)

• Record Type: Journal Article
• Authors: Lanari, M.; Anderson, E.J.; Sheridan-Pereira, M.; Carbonell-Estrany, X.; Paes, B.; Rodgers-Gray, B.S.; Fullarton, J. R.; Grubb, E.; Blanken, M.
• Is Part Of: Epidemiology and infection. Volume 148(2020)
• Publication Date: 2020-08-17
• Subjects: Epidemiology, -- Lower respiratory tract infection, -- Moderate-to-late preterm infants, -- Respiratory support, -- Respiratory syncytial virus, -- RSV hospitalisation; Communicable diseases -- Periodicals; Epidemiology -- Periodicals; 614.4
• DOI: 10.1017/S0950268820001661
• Languages: English
• ISSNs: 0950-2688

Abstract

Abstract: To provide comprehensive information on the epidemiology and burden of respiratory syncytial virus hospitalisation (RSVH) in preterm infants, a pooled analysis was undertaken of seven multicentre, prospective, observational studies from across the Northern Hemisphere (2000–2014). Data from all 32 0 –35 6 weeks' gestational age (wGA) infants without comorbidity were analysed. RSVH occurred in 534/14 504 (3.7%) infants; equating to a rate of 5.65 per 100 patient-seasons, with the rate in individual wGA groups dependent upon exposure time ( P = 0.032). Most RSVHs (60.1%) occurred in December–January. Median age at RSVH was 88 days (interquartile range (IQR): 54–159). Respiratory support was required by 82.0% of infants: oxygen in 70.4% (median 4 (IQR: 2–6) days); non-invasive ventilation in 19.3% (median 3 (IQR: 2–5) days); and mechanical ventilation in 10.2% (median 5 (IQR: 3–7) days). Intensive care unit admission was required by 17.9% of infants (median 6 days (IQR: 2–8) days). Median overall hospital length of stay (LOS) was 5 (IQR: 3–8) days. Hospital resource use was similar across wGA groups except for overall LOS, which was shortest in those born 35 wGA (median 3 vs. 4–6 days for 32–34 wGA; P < 0.001). Strategies to reduce the burden of RSVH in otherwise healthy 32–35 wGA infants are indicated.